...
机译:与核癌中的核核苷酸加内分泌治疗总体存活
Seoul Natl Univ Seoul Natl Univ Hosp Coll Med Canc Res Inst Seoul South Korea;
Natl Taiwan Univ Hosp Taipei Taiwan;
Massachusetts Gen Hosp Canc Ctr Boston MA USA;
Ludwig Maximilians Univ Munchen Breast Ctr Dept Obstet &
Gynecol Munich Germany;
Ist Europeo Oncol Div Med Senol Milan Italy;
Hosp Caridade Ijui CACON Ijui Brazil;
Org Oncol &
Translat Res Hong Kong Peoples R China;
Yonsei Univ Hlth Syst Yonsei Canc Ctr Seoul South Korea;
Natl Canc Ctr Ctr Breast Canc Gyeonggi Do South Korea;
Inst Seguridad Social Estado Mexico &
Municipios Ctr Oncol Estatal Toluca Mexico;
Hosp St Joan Despi Moises Broggi Inst Catala Oncol Barcelona Spain;
Univ Ulsan Coll Med Asan Med Ctr Seoul South Korea;
Novartis Pharmaceut E Hanover NJ USA;
Novartis Basel Switzerland;
Novartis Basel Switzerland;
Novartis Pharmaceut E Hanover NJ USA;
Novartis Pharmaceut E Hanover NJ USA;
UCLA Ctr Comprehens Canc Los Angeles CA USA;
Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;
机译:核苷酸与内分泌治疗组合提高了/周末血症乳腺癌患者的整体存活
机译:与核癌中的核核苷酸加内分泌治疗总体存活
机译:适应性循环 - 佐剂动态标记调整的个性化治疗比较内分泌治疗加上核酸与中间风险HR + / HER2-早期乳腺癌的化疗
机译:镭-223二氯化物单疗法和组合治疗唑醇或多柔比星改善了乳腺癌骨转移的小鼠模型中的存活
机译:内分泌非依赖性乳腺癌的内分泌治疗新方法
机译:将ribociclib添加到内分泌治疗的成本效果为Her-阳性海洋病女性女性患者的Her2阴性晚期乳腺癌患者
机译:Ribociclib加上内分泌治疗的成本效益与安慰剂加上内分泌治疗HR阳性,Her2阴性乳腺癌